Clinical trial · Interventional
Sodium Glycididazole Reduces the Adverse Reactions of Concurrent Chemoradiotherapy
Sodium Glycididazole Reduces Chemoradiotherapy-related Adverse Reactions During Concurrent Chemoradiotherapy for Locally Advanced Non-small Cell Lung Cancer
NCT06667622CI-TRIAL-00082088unknownPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To evaluate the efficacy and toxicity of sodium glycididazole combined with concurrent chemoradiotherapy in patients with unresectable locally advanced non-small cell lung cancer after neoadjuvant chemoradiotherapy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Chemoradiotherapy | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| sodium glycididazole | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Sodium glycididazole combined with concurrent chemoradiotherapy group
- description
- Patients with unresectable locally advanced non-small cell lung cancer after neoadjuvant chemoradiotherapy are treated with sodium glycididazole during concurrent chemoradiotherapy.
- interventionNames
- Drug: sodium glycididazole
Primary outcomes (2)
- measure
- Incidence and severity of grade 3 and above radiation esophagitis
- timeFrame
- 8 weeks
- description
- Radiation esophagitis of grade 3 or higher is graded according to the toxicity criteria of the CTCAE v5.0.
- measure
- Incidence and severity of grade 2 and above radiation pneumonitis
- timeFrame
- 8 weeks
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: 1. Patients must have histologically or cytologically confirmed non-small cell lung cancer. 2. Patients with unresectable stage II-III non-small cell lung cancer after neoadjuvant therapy. 3. ECOG PS 0-2 4. Adequate organ and bone marrow function. Exclusion Criteria: 1. History of previous radiotherapy. 2. The previous immune-related pneumonitis ≥ grade 2. 3. Local lesions require surgery. 4. History of another primary malignancy. 5. History of active primary immunodeficiency. 6. Histological findings showed mixed small cell lung cancer and non-small cell lung cancer. 7. For any unmitigated toxicity during pre-study chemoradiotherapy.
References
Publications (0)
Data not yet available
No reference posted for this study.